-
Product Insights
NewHypersomnia – Drugs In Development, 2024
Empower your strategies with our Hypersomnia – Drugs In Development, 2024 report and make more profitable business decisions. Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can have many possible causes (such as seasonal affective disorder) and can cause distress and problems with functioning. It is a pathological state characterized by a lack of alertness during the waking episodes of the day. The main symptom of hypersomnia is excessive daytime sleepiness (EDS), or prolonged nighttime...
-
Product Insights
NewPrader-Willi Syndrome (PWS) – Drugs In Development, 2024
Empower your strategies with our Prader-Willi Syndrome (PWS) – Drugs In Development, 2024 report and make more profitable business decisions. Prader-Willi syndrome (PWS) is a rare congenital genetic disorder that results in a number of physical, mental, and behavioral problems. PWS is due to the lack of several genes on one of an individual’s two chromosome 15s. In the majority of cases, there is a deletion. In the remaining cases, the entire chromosome from the father is missing and there are...
-
Product Insights
NewMyotonic Dystrophy – Drugs In Development, 2024
Empower your strategies with our Myotonic Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Myotonic dystrophy (DM), also known as dystrophia myotonica, is a group of genetic disorders characterized by progressive muscle weakness, myotonia (delayed relaxation of muscles after contraction), and various multi-systemic manifestations. It is one of the most common forms of adult-onset muscular dystrophy and can affect multiple organs and systems in the body. There are two main types of myotonic dystrophy, DM1 and...
-
Product Insights
NewMuscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The Muscular Dystrophy drugs in development market research report provide comprehensive information on...
-
Product Insights
NewCognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer's), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty...
-
Product Insights
DoT New York – I-86 Chautauqua Lake Bridge Upgrade – New York
The DoT New York – I-86 Chautauqua Lake Bridge Upgrade – New York project involves the upgrade of bridges on Interstate 86 (I-86) over Chautauqua Lake in North Harmony Town, Chautauqua County, New York, the US. Equip yourself with the essential tools needed to make informed and profitable decisions with our DoT New York – I-86 Chautauqua Lake Bridge Upgrade – New York report. Note: This is an on-demand report that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-614 in Substance (Drug) Abuse
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PF-614 in Substance (Drug) Abuse Drug Details: PF-614 (oxycodone prodrug ER) is under development for...
-
Product Insights
Kalgold Mine
The Kalgold Mine is a gold mine in South Africa. It is currently in operation. Empower your strategies with our Kalgold Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain vital...
-
Product Insights
Kusasalethu Mine
The Kusasalethu Mine is a gold mine in South Africa. It is currently in operation. Empower your strategies with our Kusasalethu Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain vital...
-
Product Insights
Mponeng Mine
The Mponeng Mine is a gold mine in South Africa. It is currently in operation. Empower your strategies with our Mponeng Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain vital...